|
From about a year ago, on DRUGS.COM...
A little more info on INCB024360 that is easier (?) to understand basics of this new treatment, maybe? 
http://www.drugs.com/clinical_trials...do1-13761.html
__________________
Ric: Low-risk MDS (blasts <4%); 4 cycles Revlimid no positive response; PRBC transfusion dependent; so far, 392'units' over 8 3/4 years; BMB #4 (15/04/01) shows evolution to AML (blasts 20-30%  ) 47,XY,del(5) (q22q35),+21[24][cp24]/46,XY(1).
Last edited by riccd2001 : Mon Aug 5, 2013 at 12:50 AM.
|